In a collaboration with Natera, we analyzed ctDNA longitudinally in 66 patients with metastatic ILC using tumor-informed Signatera assays. Sequencing results from N=355 samples showed that ctDNA testing is a promising approach for surveillance and precision medicine in patients with metastatic ILC, a setting where imaging has often limited sensitivity.
Important ILC Research: “Personalized Circulating Tumor DNA Testing for Detection of Progression and Treatment Response Monitoring in Patients With Metastatic Invasive Lobular Carcinoma of the Breast”
